Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab. A phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for ...
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
Central nervous system (CNS) outcomes and progression patterns in patients with RET fusion-positive lung cancers treated with selpercatinib. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results